Devyser Q1: A most exciting year - Redeye

Redeye reiterates its base case following the company’s Q1 report. We anticipated a soft quarter but see good prospects for an exceptionally strong H2 2025. There is a hefty upside to our DCF base case at current levels, and the shares are trading at undemanding multiples. We see reimbursement, quarterly reports and FDA timeline as key catalysts.

Länk till analysen i sin helhet: https://www.redeye.se/research/1100722/devyser-q1-a-most-exciting-year?utm_source=finwire&utm_medium=RSS